- Rating
- 2(+1)
- Confidence
- 4
- Informativeness
- 1
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
The paper proposes PharmPD, a 200-dimensional descriptor coupling pharmacophore types with 3D intercenter distances. Adding PharmPD improves performance on many TDC ADMET tasks
Critical strengths
Explicitly encoding pharmacophore types and their distances incorporates knowledge of molecular recognition into prediction.
Critical weaknesses
- The additional gain of 3D geometry over topology is unclear in table 7. And distances are sensitive to conformers, whereas topology remains unchanged across conformers, raising concerns about the robustness of PharmPD.
- The additional benefits of PharmPD are unclear. Full and Rank-1 show small differences when added to MapLight. CATS3D-style achieves higher recognition-role recovery on 2/3 targets in Table 2. Table 14 shows diminishing gains with richer baseline features.
Questions for authors
-
How sensitive is PharmPD to conformers? Does the Topology provide comparable gains when added to MapLight and the PXR baselines?
-
Under what conditions does PharmPD provide additional predictive or interpretive value?
4 comments
W2 / Q2. Conditions Under Which PharmPD Provides Additional Value
Response.
We appreciate the reviewer's question about when PharmPD contributes beyond existing representations. Our expanded experiments distinguish three aspects of this contribution: the predictive value of semantic–geometric correspondence, complementarity with existing molecular representations, and chemically grounded interpretation.
(1) Predictive value of semantic–geometric correspondence.
Our Rank-1 control preserves pharmacophore-type marginals, distance marginals, total feature mass, dimensionality, and auxiliary features while removing their pair-specific correspondence.
Restoring this correspondence improves CYP2C9, CYP2D6, and CYP3A4 inhibition by +0.0367, +0.0678, and +0.0492 AUPRC, respectively (all q = 0.0017; Table 1).
These results establish that retaining which chemical roles occur at which distances contributes predictive information beyond preserving the two marginal distributions separately.
(2) Complementarity depends on the existing representation.
We agree that the Full–Rank-1 difference becomes smaller when both representations are added to MapLight. To investigate this behavior, we conducted a controlled backbone analysis using representations ranging from 0 to 3,092 dimensions.
The Full–Rank-1 advantage showed a consistent negative association with backbone width across all three CYP inhibition endpoints (Spearman ρ = −0.829, q ≤ 0.0007). This indicates that the incremental contribution of explicit correspondence depends on the information already available to the predictor, although backbone composition also changes across comparisons.
Importantly, PharmPD retains measurable value in several tested settings:
- Against the closest-to-published CATS3D reconstruction (C5L), PharmPD improves standalone aggregate performance by +0.0378 (q = 0.0007; Table 2).
- In external PXR evaluation, adding PharmPD to Uni-Mol v2 84M + MapLight + multi-fidelity features improves RAE by +0.0067 (95% CI [+0.0029, +0.0107]; Table 22).
These findings help identify the representational settings in which explicit pharmacophore–distance features are most useful.
(3) Chemical interpretation and recognition-role recovery.
We acknowledge the reviewer's observation that CATS3D-style achieves stronger role-level attribution concentration on CYP2D6 and CYP3A4.
Our expanded relation-level analysis provides an additional perspective. Both PharmPD and CATS3D-style recover the prespecified CYP2D6 and CYP3A4 pharmacophore relations within their top three attributed pair types in 100% of model seeds. On hERG, PharmPD achieves 80% top-three recovery versus 30% for CATS3D-style (Table 30).
PharmPD also enables each attributed type–distance feature to be traced to its contributing pharmacophore centers, molecular distances, conformer-specific contributions, and aggregation. Independent reconstruction verified the resulting features for 64/64 held-out molecules (Appendix B.1).
This provides a chemically inspectable connection between model attribution and molecular structure, allowing the identified relations to be examined and computationally verified rather than treated solely as abstract feature indices.
Overall, our findings identify when explicit semantic–geometric correspondence contributes to prediction, how its incremental value changes with the surrounding representation, and how its attributed features can be connected to molecular evidence. We hope these additional analyses clarify the contribution and practical scope of PharmPD, and we appreciate the reviewer's reconsideration of the revised work.
We sincerely thank the reviewer for the constructive feedback!
We thank the reviewer for the constructive questions, which have helped us clarify these distinctions and strengthen their experimental evaluation. We would appreciate your assessment of whether the revised manuscript and additional analyses adequately address your concerns, and would welcome any further questions or suggestions.
I thank the authors for their response and additional experiments. They alleviate my concerns, and I have raised my rating to 2.
W1 / Q1. Additional Value of 3D Geometry and Conformer Robustness
Response.
We thank the reviewer for raising these important questions. We expanded our evaluation with matched topology controls, conformer sensitivity analyses, and an external PXR comparison to clarify the contribution and robustness of PharmPD's geometric representation.
(1) Contribution of 3D information beyond topology.
We reconstructed the topology control to ensure identical pharmacophore centers, chemical assignments, weights, and auxiliary features, isolating the distance representation as the experimental variable.
In the expanded 22-task analysis, appending aligned 3D features to a fixed graph-distance representation outperformed appending row-permuted features on 21/22 tasks, with nine improvements surviving multiple-testing correction (Table 11).
To further control for the potential penalty introduced by shuffled features, we conducted an additional width-matched experiment comparing graph + 3D against graph + a duplicated graph block. The 3D-augmented representation improved performance on 19/22 tasks, with a corrected improvement on Caco-2 (q = 0.033). These experiments provide complementary evidence for useful 3D relational features beyond the tested graph-distance encoding.
(2) Additional benefit above MapLight and external PXR baselines.
In the matched seven-task MapLight augmentation experiment, both representations improved the baseline, with aggregate gains of +0.0168 for PharmPD and +0.0103 for Topology (Table 10).
We additionally evaluated the corrected representations on external PXR data using 513 molecules and 96 analog-series clusters. PharmPD improved RAE over MapLight by +0.01775, compared with +0.00396 for Topology. The direct difference was +0.01380 (95% CI [-0.00013, +0.02837]), indicating a favorable but statistically unresolved comparison.
Together, these results characterize the contribution of 3D encoding across different predictive settings rather than assuming its universal superiority over topology.
(3) Conformer robustness.
PharmPD aggregates pair-distance features across generated conformers. We evaluated the stability of this representation under expanded conformer sampling.
The pooled features exhibited high split-half reliability (r = 0.963 for max pooling; r = 0.986 for mean pooling). In the three-CYP MapLight-augmentation experiment, increasing the conformer count from K = 4 to K = 64 changed aggregate performance by only +0.0021 (95% CI [-0.0009, +0.0049]).
These results indicate that the evaluated predictor is relatively stable across the tested sampling depths, despite variations in individual conformer geometries. PharmPD therefore does not require a uniquely selected molecular conformation to produce its pooled relational representation.